toxicology-congress-2018-scientifictracks-abstracts

3 / 32

Page 28
Notes:
conferenceseries.com
Volume 4 Toxicology: Open Access
ISSN: 2476-2067 Toxicology Congress 2018
March 12-14, 2018
March 12-14, 2018 Singapore
14th World Congress on
Toxicology and Pharmacology
Snake venom peptides: Potential therapeutic agents in thrombotic diseases
Fabio de Oliveira
Federal University of Uberlandia, Brazil
The snake venoms are constituted of a true biochemical arsenal, consisting of several proteins and peptides with activities
that have aroused the curiosity of researchers for centuries, in an attempt to understand its systemic action in order to
get pharmacological applications. A number of snake venom proteins that interfere on platelet aggregation have been isolated
from these venoms. However, there are no reports in the literature of small peptides interfering in aggregation. In the present
work, we identify and characterize, for the first time, a heptapeptide (BaltPAi: platelet aggregation inhibitor from B. alternatus
snake venom) and a decapeptide (BmooPAF: platelet-activating factor from B. moojeni snake venom), which potentially
inhibits and induces the platelet aggregation, respectively. BmooPAi shows a rather specific inhibitory effect on collagen-
induced platelet aggregation in human platelet-rich plasma, whereas it has little or no effect on platelet aggregation induced by
adenosine diphosphate. The results presented here suggest that the BaltPAi consists of an amino acid sequence present in the
C-terminal region of snake venom phospholipase A2 enzymes. This sequence would be responsible for the inhibition of platelet
aggregation as well as for the cytotoxicity effects of tumor cells caused by these enzymes. Assays with monoclonal antibodies
(anti-integrin α2b and anti-GP1BA) show a significant inhibitory effect on BmooPAF-induced platelet aggregation. On the
other hand, anti-GPVI antibody shows no effect on platelet function. These findings, associated with molecular docking,
indicate that BmooPAF induces platelet aggregation via binding to the GPIbα platelet receptor leading to αIIbβ3 integrin
activation. These toxins could be of medical interest as tools for the development of novel therapeutic agents for the prevention
and treatment of thrombotic disorders.
Recent Publications
1. De Queiroz, F de Oliveira, et al. (2017) The role of platelets in hemostasis and the effects of snake venom toxins on platelet
function. Toxicon; 133: 33-47.
2. F de Oliveira, et al. (2016) Biochemical and functional characterization of BmooSP: A new serine protease from Bothrops
moojeni snake venom. Toxicon ; 111(130): 138.
Biography
Fabio de Oliveira has completed his PhD in 2001 from National University of Brasília in Brazil. He was the Director of Innovation and Transfer of Technology
of the Federal University of Uberlandia. Currently he is the Professor of the postgraduate program in Genetic and Biochemistry and in Cellular and Structural
Biology of the same university. He has experience in the area of biochemistry, biophysics and biotechnology with emphasis in isolation and characterization of
pharmacologically active principles present in venom of Brazilian snakes.
Fabio de Oliveira, Toxicol Open Access 2018, Volume 4
DOI: 10.4172/2476-2067-C1-005